Chronix Biomedical is actively engaged in clinical trials to show the clinical utility of its cancer
blood tests

The first clinical trial is studying men with elevated PSA levels. The Primary Outcome Measure is to determine if copy number instability (CNI scores) derived from analysis of cell-free cancer DNA (cfDNA) in patients undergoing prostate biopsy correlates with biopsy diagnosis of prostate cancer.

Chronix Biomedical will be recruiting patients with pancreatic cancer to further study the clinical utility of its blood test to monitor treatment therapy